Like MDS and cs-AML, it is characterized, in up to 80% of cases, by mutations both in epigenetic modifiers, notably ASXL1 truncations leading to highly proliferative phenotypes, and SF genes [45, 46]. The gene discussed is ASXL1; the disease is myelodysplastic syndrome.